Evaluation of prophylactic and therapeutic effects of silymarin on mebendazole-induced hepatotoxicity in cats
- 108 Downloads
The aim of this study was to determine the protective action of silymarin on mebendazole-induced hepatotoxicity in cats. Twenty five healthy cats were randomly allotted into five equal groups. Cats in group A were given mebendazole (single dose 200 mg⁄kg, p.o.); group B consisted of cats that received silymarin (single dose 30 mg⁄kg, p.o.) concurrent with mebendazole administration; groups C, D and E were treated as group B, but silymarin was administered 2, 12 and 24 h after mebendazole administration, respectively. The serum concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and total and direct bilirubin were measured before mebendazole administration and 2, 12, 24 and 72 h later as indices of liver injury. A single oral administration of mebendazole significantly elevated serum concentrations of ALT, AST, ALP, LDH (in all cases), and total and direct bilirubin in one cat in group A, after 24 h (P < 0.05). In groups B and C, levels of serum enzyme activities and total and direct bilirubin remained within normal values, but in group D, levels of serum enzyme activity (in four cases) were higher than normal values and total and direct bilirubin remained within the normal range. In group E, levels of serum enzyme activities (in all cats) and total and direct bilirubin (in one cat) were higher than normal values. In conclusion, silymarin can protect liver tissue against oxidative stress in cats with mebendazole intoxication particularly in the first 2 h after exposure.
KeywordsSilymarin Hepatotoxicity Mebendazole Cat
The authors wish to express their gratitude to the research council of Shahid Chamran University of Ahvaz for their financial support.
- Boothe DM (2001) Small animal clinical pharmacology and therapeutics, 1st edn. W.B. Saunders Co, Philadelphia, pp 444–538Google Scholar
- EMEA, The European Agency for the Evaluation of Medical Products Veterinary Medicines Evaluation Unit (2001) EMEA/MRL/625/99-FINAL July 1999. http://www.emea.eu.int Seven West ferry Circus, Canary Wharf, London, UK
- Hsu WH (2008) Handbook of veterinary pharmacology, 1st edn. Wiley-Blackwell, Iowa, pp 84–112Google Scholar
- Janssen-Cilag P (2005) Information for health professionals. Ltd. Newmarket, AucklandGoogle Scholar
- Kahn CM (2007) The Merck/Merial manual for pet health. Home Edition. 1st edn. pp 77–126Google Scholar
- Kayne SB, Jepson MH (2004) Veterinary Pharmacy. 1st edn. Publications division of the Royal Pharmaceutical Society of Great Britain, pp 343–423Google Scholar
- Lappin MR (2001) Feline internal medicine secrets, 2nd edn. Hanley Belfus Inc, Philadelphia, pp 158–161Google Scholar
- Maddison J, Page S, Church D (2002) Small Animal Clinical Pharmacology. 1st edn. W.B. Saunders Co, Harcourt Publishers, pp 106–339Google Scholar
- Paulova J, Dvorak M, Kolouch F, Vanova L, Janeckova L (1990) Verification of the hepatoprotective and therapeutic effect of silymarin in experimental liver injury with tetrachloromethane in dogs. Vet Med (Praha) 35:629–635Google Scholar
- Tilley LP, Smith FWK (2005) The 5-minute veterinary consult, 3rd edn. Lippincott Williams and Wilkins, Maryland, pp 1325–1326Google Scholar
- Wellington K, Jarvis B (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio Drugs 15:465–489Google Scholar